肾脏mTORC1激活与狼疮肾炎疾病活动度及预后相关
这项回顾性研究纳入187例狼疮肾炎(LN)患者、20例糖尿病肾病(DN)患者、10例微小病变(MCD)患者和10例正常对照(NC),评估肾脏mTORC1/2激活与临床病理指标及预后的关联。结果显示mTORC1(而非mTORC2)激活与血清白蛋白、补体C3、蛋白尿及新月体形成、间质炎症和纤维化等病理标志物强相关,并可作为LN患者的预后标志物。
要点
- mTORC1在LN患者足细胞、系膜细胞、内皮细胞和肾小管上皮细胞中显著激活。
- mTORC1(而非mTORC2)激活与血清白蛋白、补体C3、蛋白尿及新月体形成、间质炎症和纤维化强相关。
- mTORC1激活被确定为LN患者的预后标志物,并伴有补体激活、抗原呈递和吞噬作用增强。
核心结论
- 肾脏mTORC1激活可能作为揭示LN患者疾病活动度并预测临床预后的生物标志物。
研究设计与样本
- 回顾性研究纳入187例LN患者、20例DN患者、10例MCD患者和10例NC,其中7例LN患者有重复肾活检。
- 采用免疫组织化学和多路免疫荧光评估mTORC1/2激活,并对20例LN患者肾活检组织进行蛋白质组学分析。
主要发现
- 与MCD或NC相比,LN患者足细胞、系膜细胞、内皮细胞和肾小管上皮细胞中mTORC1/2显著激活。
- LN患者肾小球mTORC1激活高于DN患者。
- mTORC1(而非mTORC2)激活与血清白蛋白、补体C3、蛋白尿及新月体形成、间质炎症和纤维化强相关。
- mTORC1激活被确定为LN患者的预后标志物。
- 蛋白质组学与免疫组化数据的生物信息学分析显示,mTORC1激活的LN患者补体激活、抗原呈递和吞噬作用增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was initiated to evaluate mammalian target of rapamycin (mTOR) activation in renal tissue of LN patients. METHODS: This retrospective study included 187 LN patients, 20 diabetic nephropathy (DN) patients, 10 minimal change disease (MCD) patients and 10 normal controls (NCs). Seven of 187 LN patients had repeated renal biopsies. mTORC1/2 activation was evaluated by immunohistochemistry and multiplexed immunofluorescence. The association of mTORC1/2 activation with the clinicopathologic indices and prognostic outcomes was analysed among 187 LN patients. Proteomics was performed in renal biopsies of 20 LN patients. Proteomics was employed to comprehensively evaluate the impact of mTOR activation on intrarenal gene expression. RESULTS: mTORC1/2 was significantly activated in podocytes, mesangial cells, endothelial cells and tubular epithelial cells of LN patients as compared with those with MCD or NC. The glomerular mTORC1 activation was higher in LN patients compared with DN patients. mTORC1, but not mTORC2, activation strongly correlated with serum albumin, complement C3, proteinuria and the following pathological biomarkers of LN: crescent formation, interstitial inflammation and fibrosis. Moreover, mTORC1 activation was identified as a prognostic marker in LN patients. Bioinformatic analyses of proteomics and immunohistochemical data unveiled increased complement activation, antigen presentation and phagocytosis in LN patients with mTORC1 activation. CONCLUSION: Renal mTORC1 activation could be a biomarker to reveal disease activity and predict clinical prognosis in LN patients.
引用
- Mao Z, Tan Y, Tao J, et al. Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. Rheumatology (Oxford). 2022. PMID: 35040950. doi:10.1093/rheumatology/keac037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。